Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Company Deals

MediTrust Mabwell Insurance Ecosystem Partnership

Fineline Cube Feb 5, 2026
Company Deals

Pfizer Launches Migraine Management Zone at China Pharmacy

Fineline Cube Feb 5, 2026
Company Deals

Takeda Ends $128M Kyoto University iPSC Project After Decade of Research

Fineline Cube Feb 5, 2026
Company Deals Digital

Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System

Fineline Cube Feb 5, 2026
Hospital Policy / Regulatory

Beijing Online Consultation Pilot Gets NHC Approval for Children’s Care

Fineline Cube Feb 5, 2026
Company Drug

Hanx Biopharma HX111 ADC Begins Phase I Trial for Lymphoma and Solid Tumors

Fineline Cube Feb 5, 2026
Company Drug

Shouyao’s SY-9453 MAT2A Inhibitor Gets NMPA Nod for MTAP-Deleted Tumors

Fineline Cube Feb 5, 2026
Company Drug

Luye Pharma’s Lurbinectedin for Metastatic SCLC Wins Macau Regulatory Nod

Fineline Cube Dec 5, 2023

Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced that Macau’s medical products...

Company Drug

Yantai Dongcheng Pharmaceutical Gets NMPA Green Light for FAP-Targeting Radiotherapeutic Drug

Fineline Cube Dec 5, 2023

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has received approval...

Company Drug

Tonghua Dongbao Pharmaceuticals Secures NMPA Approval for Biosimilar Liraglutide

Fineline Cube Dec 5, 2023

Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced that it has received...

Company Drug

Simcere Pharmaceutical’s SIM0501 Receives FDA Approval for Advanced Solid Tumor Clinical Trial

Fineline Cube Dec 5, 2023

Simcere Pharmaceutical Group (HKG: 2096) has announced that it has received clinical trial approval from...

Company

WuXi Biologics Shares Plunge 22% on Slower CDMO Industry Growth and Revenue Shortfall

Fineline Cube Dec 5, 2023

WuXi Biologics (HKG: 2269) experienced a 22% decline in its share price on Monday, December...

Company Deals

Abbisko Therapeutics Strikes Licensing Deal with Merck KGaA for CSF-1R Inhibitor Pimicotinib

Fineline Cube Dec 5, 2023

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced a licensing agreement...

Company Deals

Boehringer Ingelheim Partners with Shanghai Handu Pharma to Enhance Oral Medication Delivery

Fineline Cube Dec 5, 2023

Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Shanghai Handu...

Company Deals

Gedeon Richter Acquires Rights to Mithra’s Contraceptive and Menopause Treatments for Chinese Market

Fineline Cube Dec 5, 2023

Gedeon Richter Plc, a Hungarian pharmaceutical company, and Belgium’s Mithra (OTCMKTS: MITPF) have entered into...

Company Deals

Aspen Pharmacare Holdings to Boost China Presence with Full Acquisition of Sandoz’s Subsidiary

Fineline Cube Dec 5, 2023

Aspen Pharmacare Holdings (JSE: APN), a South Africa-based pharmaceutical company, is poised to enhance its...

Company Drug

AstraZeneca Halts Late-Stage Trials for Lokelma in Hyperkalemia Due to Timing and Event Rate Issues

Fineline Cube Dec 5, 2023

AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, has announced the termination of two...

Company Deals

Roche Expands Beyond Oncology with USD 2.7 Billion Carmot Therapeutics Acquisition

Fineline Cube Dec 5, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has entered into an agreement to acquire U.S. biotech...

Company Drug

Stem-Cell Startup Xellsmart Earns FDA Orphan Drug Designation for ALS Therapy

Fineline Cube Dec 5, 2023

Xellsmart, a stem-cell startup headquartered in Suzhou, has announced that it has received orphan drug...

Company Drug

Worg Pharmaceuticals Gets FDA Approval for Phase II Graves’ Disease Study

Fineline Cube Dec 5, 2023

Worg Pharmaceuticals, a Hangzhou-based developer of allergic drugs, has received the green light from the...

Company Drug

Nanchang Baiji Pharmaceutical’s Budesonide Nasal Spray Approved by China’s NMPA

Fineline Cube Dec 5, 2023

Nanchang Baiji Pharmaceutical Co. Ltd., a Chinese pharmaceutical company, has received approval from the National...

Company Drug

Eli Lilly’s Jaypirca Receives FDA Accelerated Approval for Chronic Lymphocytic Leukemia

Fineline Cube Dec 5, 2023

The US Food and Drug Administration (FDA) has granted Eli Lilly (NYSE: LLY) an accelerated...

Company Deals

Autobio Diagnostics and China National Medical Device Form Strategic Partnership

Fineline Cube Dec 5, 2023

Autobio Diagnostics Co., Ltd (SHA: 603658), a Chinese in-vitro diagnostics company, has entered into a...

Company Medical Device

Valgen Secures NMPA Approval for China’s First Transcatheter Mitral Valve Clamp System

Fineline Cube Dec 4, 2023

Hangzhou-based Valgen Holding Corporation has received market approval from the National Medical Products Administration (NMPA)...

Company Drug

Ambio Gains FDA Approval for Generic Forteo, Challenging Eli Lilly’s Osteoporosis Market

Fineline Cube Dec 4, 2023

Ambio has secured regulatory approval from the U.S. Food and Drug Administration (FDA) for its...

Company Drug

Chinese Firms Secure EUAs for Omicron XBB Vaccines Amid Dominant Variant Surge

Fineline Cube Dec 4, 2023

A wave of Chinese pharmaceutical companies has announced the receipt of Emergency Use Authorizations (EUAs)...

Company Drug

Pfizer’s Danuglipron Phase IIb Trial Achieves Weight Loss Goals Amid Tolerability Concerns

Fineline Cube Dec 4, 2023

Pfizer (NYSE: PFE) announced last week that its Phase IIb trial evaluating danuglipron, a glucagon-like...

Posts pagination

1 … 388 389 390 … 620

Recent updates

  • Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength
  • Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion
  • Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal
  • GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength
  • MediTrust Mabwell Insurance Ecosystem Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength

Company

Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Company Medical Device

GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.